Kuros Biosciences Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0325814116
CHF
28.42
-1.7 (-5.64%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Kuros Biosciences Ltd. stock-summary
stock-summary
Kuros Biosciences Ltd.
Pharmaceuticals & Biotechnology
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Company Coordinates stock-summary
Company Details
Wagistrasse 25 , SCHLIEREN None : 8952
stock-summary
Tel: 41 44 7334747
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Clemens van Blitterswijk
Chairman of the Board of Directors
Dr. Joost de Bruijn
Chief Executive Officer, Member of the Board of Directors
Ms. Leanna Caron
Vice Chairman of the Board of Directors
Dr. Scott Bruder
Member of the Board of Directors
Mr. Jason Hannon
Member of the Board of Directors
Mr. Oliver Walker
Member of the Board of Directors
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Dec 2013)
Net Profit:
-10 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 1,216 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.19

stock-summary
Return on Equity

-40.21%

stock-summary
Price to Book

15.86